Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
FOL-005 Phase 2a Trial Data Released By Follicum
After a hiatus of two years, Follicum, under new management, re-emerges to present new interesting data from their phase 2a study which was originally thought to miss its endpoint. Head to the Articles page for a full presentation from Follicum and a look at trichoscans from the trial, such as the page seen below.
Kintor US Phase 2 Trial Results Leading Towards US Phase 3 Trial
Check out the latest article with further details on how KX-826 aka pyrilutamide faired in a US phase 2 trial comprising male subjects, and also how the results compared to Kintor's China phase 2 trial of KX-826. Spoiler alert, the US phase 2 trial was successful, but it differed from the phase 2 results in China.
STEMON Promo Added
The first "promo" post has been added to the Promos page. These are short posts about companies, products, or ideas which meet the criteria to be shared on Follicle Thought, but may be in a different category than front page news. Stemon Inc has developed an interesting hair growth exosome technology which is not available for sale, but should likely be evaluated further in a small clinical study.
CosmeRNA Release Update
Following the release of a new CosmeRNA-themed article in the Korean press, there is reason to believe that CosmeRNA should finally be releasing next month. Head to to the Articles page to get the full scoop.
Kintor Doses First GT20029 Patient In Phase 2 Trial In China
Kintor Pharmaceutical's second drug for AGA, GT20029, which is an androgen receptor degrader drug and thought to be more advanced than KX-826/pyrilutamide, has entered into a phase 2 trial.
- The trial is a multi-center, double-blind, placebo-controlled study.
- It will enroll 180 male patients in China.
- The primary endpoint will be change from baseline in non-vellus target area hair counts (TAHC) after 12 weeks of treatment in comparison to placebo.
Industry Update Spring 2023
A new article was published today detailing some of the more interesting and obscure happenings in the hair growth treatment industry. Head to the home page or Articles page to read what's new.
Amplifica Eyes Trial This Year 2023
A new writeup which was featured on the UC Irvine News website titled "Huting for cures to hair loss" detailed the works of Dr. Maksim Plikus, a research scientist, and Dr. Natasha Mesinkovska, a dermatologist and research scientist. Dr. Plikus is well known for his work studying hairy moles which appear on human skin and for his co-founding of the biotech company Amplifica. Notably, the UCI article mentions that "Human trials on the company’s lead compound are expected to begin later this year." The company mentioned, of course, being Amplifica.
Kintor Completes Enrollment For Phase 3 Trial in China
Announced today through a company press release, Kintor has completed enrollment of 740 male subjects in its phase 3 trial of pyrilutamide aka KX-826 for the treatment of androgenic alopecia. This means that the latest subjects to enter the trial still need to complete their 24 weeks of dosing of the drug or placebo depending on which they received. Kintor is hopeful that pivotal data from this important phase 3 trial will readout later this year in Q4 2023. The company also announced in today's release that the US phase 2 trial for male AGA is expected to readout its data in Q2 2023.
OliX Pharmaceuticals Receives Approval For Phase 1 Trial & Plans Cosmeceutical
OliX Pharmaceuticals of Korea announced today the approval from a regulatory committee in Australia to begin a phase 1 clinical trial for OLX72021, the new development name of its therapy for androgenic alopecia. The planned trial will be a multi-center, randomized, double-blind, placebo-controlled, and single ascending dose phase 1 study, according to today's release. Perhaps even more interesting, OliX's founder Dr. Dong Ki Lee stated that the company also plans to develop a cosmeceutical version of OLX72021 after safety is confirmed in the upcoming phase 1 trial. This would make the second androgen receptor siRNA cosmeceutical on the horizon after the the popular CosmeRNA which intends to launch soon.
Rion Trialing Topical Exosome Product
Rion Aesthetics, a branch of the Rion Therapeutics company, is trialing a topical exosome-based hair growth product, according to its website. Last June, Follicle Thought published an article featuring Rion and other exosome companies who are delving into hair loss therapies. Since then, the information about Rion's work in hair growth has shifted to the Rion Aesthetics website. I reached out to Rion Aesthetics who told me that they are seeking to release a topical "cosmetic" product for scalp/hair health later this year in 2023. They also mentioned potentially initiating a FDA clinical trial for an injectable version of their exosome product for hair growth later this year.
Rion Aesthetics currently sells a topical exosome-derived product for skincare called plated. If their exosome product for hair growth pans out it could provide an option for those who avoid drug-based topicals, and could also bolster regimens which include them. Note that the pricing of Rion's first skincare product is quite premium.